Brief: Allarity Therapeutics Provides Updates For Ixempra And Stenoparib Phase 2 Monotherapy Clinical Studies
28/03/2023 11:04
March 28 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* ALLARITY THERAPEUTICS PROVIDES UPDATES FOR IXEMPRA AND
STENOPARIB PHASE 2 MONOTHERAPY CLINICAL STUDIES
* ALLARITY THERAPEUTICS INC - INTERIM DATA READOUTS FOR BOTH
STUDIES ANTICIPATED IN H2 2023
* ALLARITY THERAPEUTICS INC - INTERIM DATA READOUTS FOR BOTH
STUDIES ANTICIPATED IN H2 2023.
* ALLARITY THERAPEUTICS INC: EFFORTS UNDERWAY TO ACCELERATE
PATIENT RECRUITMENT AND AMEND PROTOCOLS TO IMPROVE PATIENT
OUTCOMES
* ALLARITY THERAPEUTICS: SLOWER THAN ANTICIPATED PATIENT
ENROLLMENT IN BOTH STUDIES, OWING IN PART TO IMPACTS OF COVID
PANDEMIC ON TRIAL SITE STAFFING
Source text for Eikon: ID:nGNXv6vNP
Further company coverage: ALLR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic